This is a free translation into English of the Financial Report issued in French and it is provided solely for the convenience of English-speaking users.
Half-Year
Financial Report
June 30, 2026
Median Technologies SA
This is a free translation into English of the Financial Report issued in French and it is provided solely for the convenience of English-speaking users.
P a g e | - 2 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
MEDIAN TECHNOLOGIES - PRESENTATION OF THE GROUP
Median Technologies is a French joint stock company (Société Anonyme) with a Board of Directors, founded in 2002 and domiciled in France. Our Company is located in the Sophia Antipolis Technopole in the Alpes Maritimes region of France, where our head office is based. This site brings together most of our teams, including all Research and Development (R&D) staff for our two activities, iCRO and eyonis®. Our Company also has several operational and commercial subsidiaries:
Median Technologies Inc. in the United States.
Median eyonis inc. in the United States;
Median Medical Technology (Shanghai) Co, Ltd. in China.
The Company has been listed on the Euronext GROWTH market in Paris since 2011.
(Mnemonic code: ALMDT - ISIN: FR0011049824). Median has been labeled “Innovation.
P a g e | - 3 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
MEDIAN TECHNOLOGIES - PRESENTATION OF THE GROUP .................................... - 2 - A. OVERVIEW ............................................................................................................................................ - 4 - B. MEMBERS OF THE BOARD OF DIRECTORS ........................................................................................ - 9 - C. FUND-RAISING HISTORY SINCE THE IPO ........................................................................................ - 11 - D. SHAREHOLDING STRUCTURE AS OF JUNE 30, 2026 ....................................................................... - 12 - CONDENSED INTERIM FINANCIAL STATEMENTS .................................................. - 13 - A. CONSOLIDATED STATEMENT OF FINANCIAL POSITION ................................................................ - 14 - B. CONSOLIDATED STATEMENT OF NET INCOME ............................................................................... - 15 - C. CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME .......................................... - 15 - D. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY ................................................................. - 16 - E. CONSOLIDATED STATEMENT OF CASH FLOWS .............................................................................. - 17 - F. NOTES TO THE FINANCIAL STATEMENTS (IN ACCORDANCE WITH IFRS ...................................... - 18 - NOTE 1 Overview of major events ............................................................................................................. - 18 - NOTE 2 Accounting principles, valuation methods, IFRS options used ................................................ - 21 - NOTE 3 Intangible assets ........................................................................................................................... - 23 - NOTE 4 Tangible assets .............................................................................................................................. - 23 - NOTE 5 Non-current financial assets ....................................................................................................... - 24 - NOTE 6 Trade receivables .......................................................................................................................... - 24 - NOTE 7 Current financial assets ............................................................................................................... - 25 - NOTE 8 Other current assets ..................................................................................................................... - 25 - NOTE 9 Cash and cash equivalents .......................................................................................................... - 26 - NOTE 11 Equity ............................................................................................................................................. - 28 - NOTE 12 Personnel commitments .............................................................................................................. - 32 - NOTE 13 Current and non-current provisions ............................................................................................ - 34 - NOTE 14 Financial liabilities ........................................................................................................................ - 34 - NOTE 15 Deferred tax liabilities ................................................................................................................... - 42 - NOTE 16 Trade payables and other current liabilities ............................................................................... - 43 - NOTE 17 Contracts Liabilities ...................................................................................................................... - 43 - NOTE 18 Revenue ......................................................................................................................................... - 44 - NOTE 19 External expenses ......................................................................................................................... - 45 - NOTE 20 Staff costs ...................................................................................................................................... - 46 - NOTE 21 Taxes .............................................................................................................................................. - 46 - NOTE 22 Share-based payments ................................................................................................................ - 47 - NOTE 23 Financial income (expense) ......................................................................................................... - 52 - NOTE 24 Income tax ..................................................................................................................................... - 52 - NOTE 25 Earnings per share ........................................................................................................................ - 53 - NOTE 26 Off-balance-sheet commitments and other contingent liabilities ........................................... - 54 - NOTE 27 Related transaction ...................................................................................................................... - 56 - NOTE 28 Dividends ....................................................................................................................................... - 57 - NOTE 29 Events after the reporting period ................................................................................................. - 58 -
MEDIAN TECHNOLOGIES - DECLARATION OF THE PERSON RESPONSIBLE FOR THE
FINANCIAL REPORT ON THE CONDENSED INTERIM FINANCIAL STATEMENTS ....... - 59 -
P a g e | - 4 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
A. OVERVIEW
Turning Medical Images into Actionable Insights for Better Patient Care
Median Technologies contributes to the fight against cancer by generating actionable clinical insights from patients’ medical images. We are an innovative health technology company specializing in medical imaging.
We deploy proprietary artificial intelligence (AI), computer vision, and signal processing technologies to develop and commercialize Software as Medical Devices (SaMD) designed to transform routine medical image analysis. We also enable the optimal use of imaging data in clinical trials and drug development programs conducted by pharmaceutical and biotechnology companies.
We specialize in oncology imaging, a therapeutic area where medical imaging plays a critical role throughout the patient journey and across all solid tumor cancers, which represent approximately 90% of all cancers. Today, we operate in the United States, the world’s largest healthcare and clinical trials market, as well as in Europe and China, a rapidly growing region for healthcare innovation and clinical development. We address two healthcare markets: drug development and patient care, delivering value through three complementary levels of expertise:
1. Optimizing imaging management in oncology clinical trials: we provide centralized imaging services supported by our proprietary medical image management and analysis technologies. We manage the entire imaging workflow of oncology clinical trials, streamline image operations through an integrated quality framework, and generate critical efficacy data supporting the evaluation of oncology drug candidates.
2. Leveraging AI technologies to generate more actionable data in oncology clinical trials: we collaborate with pharmaceutical companies to identify patients at earlier stages of disease for enrollment in clinical trials, discover predictive imaging biomarkers, and develop companion diagnostics using our proprietary AI technologies.
3. Enabling earlier and more accurate cancer diagnosis through Artificial Intelligence: we develop and commercialize AI-powered Software as Medical Devices designed to support the early detection and diagnosis of cancer in routine clinical practice, particularly within organized cancer screening programs.
Meaningful Clinical and Technology Partnerships
Since the Company’s inception, we have established trusted partnerships with leading medical centers worldwide and developed strategic collaborations with globally recognized technology leaders in their respective fields. These partnerships contribute to the scientific rigor, technological innovation, and operational excellence that underpin our solutions and services.
P a g e | - 5 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
Behind Our Technology: Our People
At Median Technologies, our people are the foundation of our success. Guided by a shared commitment to innovation, patients, customers, and quality, our teams work every day to advance the use of medical imaging and artificial intelligence in healthcare.
We are driven by four core values:
Bringing purpose to healthcare innovation
Keeping patients at the center of our mission
Helping our customers achieve their objectives
Promoting quality as a cornerstone of both our expertise and our culture.
These values define who we are, shape the way we work, and guide the decisions we make across the organization.
Through our technologies, our scientific expertise, and our commitment to excellence, we are transforming the way medical images are used in clinical development and patient care. By extracting advanced imaging biomarkers from medical images in a non-invasive manner, we help accelerate the development of new therapies, improve disease diagnosis, and support better treatment decisions.
Ultimately, our mission is simple: to make a meaningful difference in patients’ lives. Every day, we strive to advance healthcare innovation with the goal of improving outcomes for millions of patients worldwide. Two Business Units Serving Two Dimensions of Healthcare Innovation: Therapeutic Innovation and
Medical Device Software Innovation
Our Company is organized around two business units: eyonis®, dedicated to developing and commercializing Software as Medical Devices that enable earlier and more accurate cancer diagnosis through medical imaging; and iCRO, dedicated to maximizing the value of medical imaging in oncology drug development programs and clinical trials.
P a g e | - 6 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
With eyonis®, our ambition is to transform the paradigm of cancer imaging diagnosis. We develop Software As Medical Devices leveraging Artificial Intelligence and Machine Learning technologies to help healthcare professionals diagnose cancers earlier and more accurately from medical images. Our ambition is to become a global leader in early cancer diagnosis through AI-powered medical imaging solutions and to help transform the clinical management of cancer patients. This ambition is based on a wellestablished medical reality: the earlier cancer is detected, the greater the patient’s chances of survival. Early diagnosis is a fundamental enabler of preventive medicine, which we believe represents the future of healthcare.
Today, eyonis® primarily targets two high-impact cancers that represent major public health challenges:
Lung Cancer: Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for approximately 1.9 million deaths and 19.1% of all cancer deaths in 20241. The global five-year survival rate for lung cancer patients remains approximately 20% across all stages of the disease2. This low survival rate is largely attributable to the fact that lung cancer is typically asymptomatic in its early stages and is therefore often diagnosed late. By contrast, patients diagnosed at the earliest stage of disease (T1aN0M0) have a 20-year survival rate of approximately 95%3. These figures illustrate why the early detection of lung cancer through screening programs represents one of the most important opportunities to improve patient outcomes and addresses a major public health challenge.
Primary Liver Cancer: Hepatocellular carcinoma (HCC) accounts for more than 80% of primary liver cancers. Liver cancer is the third leading cause of cancer-related mortality worldwide, and its incidence continues to increase4. Despite therapeutic advances, prognosis remains poor, with an overall five-year survival rate below 20%. When diagnosed at an early stage, however, hepatocellular carcinoma can be treated through surgical resection or liver transplantation, resulting in five-year overall survival rates ranging from 50% to 70%5.
P a g e | - 7 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group eyonis® Software as Medical Device Portfolio: Positioning and Development Status
Following five years of clinical, regulatory, and technological development, Median Technologies obtained marketing authorizations during the first half of 2026 for its first Software as a Medical Device, eyonis® LCS (Lung Cancer Screening), designed to support the early detection of lung cancer in screening pathway. The device received FDA 510(k) clearance in February 2026 enabling commercialization across the U.S., followed by CE Mark certification in July 2026, enabling commercialization across Europe. During the period, Median Technologies also entered into strategic commercial partnerships with Tempus AI and Olea Medical, a Canon Medical Group company, to distribute eyonis® LCS in the U.S. and Europe. As of today, eyonis® LCS is the only commercially available AI-based Software as Medical Device integrating both pulmonary nodule detection and diagnostic assessment capabilities (CADe/CADx)6, specifically designed for lung cancer screening workflows and commercially available in both the United States and Europe.
The population eligible for lung cancer screening in the United States is estimated at 14.5 million individuals under the 2021 USPSTF criteria, while the 2023 American Cancer Society recommendations cover an estimated population of 19 million individuals. The maturity of lung cancer screening programs in the United States, combined with the availability of reimbursement codes supporting the use of eyonis® LCS, make the U.S. the primary target market for the solution. Applying the same USPSTF 2021 eligibility criteria, the eligible population in Europe is estimated at approximately 22 million people. National screening programs are progressively being implemented across European countries.
Following FDA clearance and CE Mark approval obtained during the first half of 2026, eyonis® transitioned from a research and development organization into a commercial operation. Commercial deployment of eyonis® LCS in the United States is being conducted through Median’s U.S. subsidiary, eyonis Inc. At the same time, development programs targeting liver cancer (HCC) and Incidental Pulmonary Nodules (IPN) advanced throughout the first half of 2026.
6 A radiological CADe device is “intended to identify, mark, highlight, or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation by the clinician.” A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease.” (Source: FDA)
P a g e | - 8 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group iCRO provides AI-powered medical imaging management and analysis services for oncology clinical trials.
Our customers include pharmaceutical companies and biotechnology organizations developing new oncology therapies, Oncology is currently the therapeutic area with the largest number of clinical trials worldwide and the highest level of R&D investment across the biopharmaceutical industry. iCRO is a commercial business that currently generates all of the Company’s revenue. The iCRO business is built around two complementary pillars: imaging workflow management services for clinical trials and the use of our proprietary iSee® imaging platform for image review and analysis.
Median Technologies delivers central imaging services through its headquarters in France for the European market, its Boston-based subsidiary for the U.S. market, and its Shanghai subsidiary for China and the broader East Asia region.
Today, the Group works with more than 95 pharmaceutical and biotechnology companies worldwide. Median Technologies also partners with leading global CROs, whose traditional clinical trial management expertise is enhanced by our imaging technologies and services. We provide imaging services across all phases of oncology drug development, from Phase I through Phase III clinical trials. As of June 30, 2026, Median Technologies had participated in 365 clinical trials, including 148 Phase III studies, which represent the pivotal trials that support regulatory approval and commercialization of new oncology therapies. Our imaging services offering is built around iSee®, our proprietary imaging platform:
iSee® provides expert image review capabilities, automating and standardizing the detection, selection, and measurement of solid tumors while enabling longitudinal assessment of patient response to treatment, a key endpoint in evaluating investigational oncology therapies.
iSee® supports both standard and advanced imaging biomarker measurements, using a broad range of imaging criteria, from RECIST 1.1 to more advanced methodologies including lesion volumetrics, mRECIST, and iRECIST.
iSee® enables image analysis across all solid tumor types, supporting a wide range of oncology clinical development programs.
Since May 2022, Median Technologies has expanded its iCRO offering with a portfolio of services that integrate Artificial Intelligence into oncology drug development programs. This second service line is marketed under the name Imaging Lab.
Imaging Lab addresses the evolving needs of the pharmaceutical industry, particularly the growing development of therapies targeting patients with early-stage cancers, a major paradigm shift currently reshaping oncology drug development.
Through AI-powered technologies, Imaging Lab provides innovative solutions across several critical dimensions of clinical trial success. It enables the identification and enrollment of patients diagnosed at earlier stages of disease and supports the discovery of predictive imaging biomarkers associated with response to investigational therapies. The objective is to optimize the clinical development pathway of new drug candidates by supporting more informed Go/No-Go decisions and improving the overall probability of clinical trial success. This challenge is particularly important in oncology, where clinical development success rates remain significantly lower than in most other therapeutic areas and where the average cost of bringing a new therapy to market is estimated at approximately $2.8 billion, compared with roughly $1 billion for other therapeutic categories7.
P a g e | - 9 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
B. MEMBERS OF THE BOARD OF DIRECTORS
Our Board of Directors provides key expertise from the industrial, clinical, financial and strategic fields. It is chaired by Oran Muduroglu.
ORAN MUDUROGLU - Chairman
Oran Muduroglu is a well-known figure in healthcare technologies, having successfully developed solutions that improve quality and access to health information. Oran benefits from over 30 years' experience in the health industry and has held CEO and Board member positions at companies such as Verily, Medicalis, Philips Medical Systems and Stentor. He graduated in engineering sciences from King’s College London.
FREDRIK BRAG - Chief Executive Officer and Director
Fredrik Brag founded the company in 2002, bringing years of expertise in business development, fund-raising operations and Initial Public Offerings (IPOs) for technology companies.
Previously, he was Vice President for HealthCenter/Focus Imaging, a position in which he gained significant experience in the field of specialized medical imaging and information and communications technologies. He graduated from the Stockholm School of
Economics.
OERN STUGE - Director
Dr. Oern Stuge is President of Orsco Life Sciences AG. Oern has participated in company development projects resulting in 7 successful disposals and IPOs. Prior to founding Orsco, he worked for Medtronic, Inc. for 12 years as a member of the Group's Executive Committee, as well as its Operations Committee. Dr. Stuge successfully conducted a repositioning of Medtronic’s Cardiac Surgery business on a global scale. Under his leadership, Medtronic founded the Structural Cardiopathy division and launched and marketed the first percutaneous cardiac valve in the world. He graduated from the Oslo University of Medicine and holds a Master of Business Administration (MBA) from the IMD Business School in
Lausanne, Switzerland.
KAPIL DHINGRA - Director
Dr. Kapil Dhingra is the head of KAPital Consulting, and also a member of the Board of Directors of several companies in the life sciences domain, namely Advanced Accelerator Applications, Exosome Diagnostics Inc., Autolus, and Five Prime, Inc. In the past, he has sat on the Boards of Directors of companies such as Biovex, Micromet, Algeta, and YM
Biosciences which were subsequently acquired by major pharmaceutical groups. Dr.
Dhingra also worked for more than 25 years in oncology research and development, including nine years at Hoffman-La Roche where he held multiple positions, notably Vice President, Director of Strategy for Oncology and Director of Clinical Development in Oncology.
P a g e | - 10 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
TIM HAINES - Director
Tim Haines is a Managing Partner at Abingworth. He has more than 30 years of experience in international management in both public and private companies within the life sciences industry. Tim is a Board member in numerous companies forming part of Abingworth’s portfolio. Tim holds a Bachelor of Science (BSc) from the University of Exeter and an MBA from INSEAD Business School.
BEN MCDONALD - Director
Ben McDonald is co-founder, partner and chief investment officer at Aegis Group Partners, a deep technology investment firm. He oversees Aegis Group Partners' investments in a range of industrial sectors including artificial intelligence, software, biotechnology, quantum computing, biomaterials and CleanTech. Ben McDonald is a graduate of the
University of Cambridge (Master of Business Administration) and Western University
(Honors Business Administration Program).
DIDRIC CEDERHOLM - Director
Didric Cederholm is a Founding Partner and the Chief Investment Officer of Lion Point Capital, a global special situations investment fund. Prior to founding Lion Point Capital, Didric spent nearly eight years at Elliott Management and was previously a Principal at Eos Partners.
Didric graduated in 2003 with honors from Columbia Business School, where he was a
Fulbright Scholar, and has a LLM from Stockholm University, where he graduated in 2001. From 1997-1999, Didric served in the Swedish Armed Forces as an Interrogation Officer and later as a 2nd Lieutenant in Swedish Military Intelligence.
P a g e | - 11 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
C. FUND-RAISING HISTORY SINCE THE IPO
Share capital prior to listing 4,349,482 217,474€
2010 /
Capital increase in cash.
Shares issued following the exercise of free Shares, founder's share warrants, and BSA. The Company issued 1 B preference share.
E Preference shares issued following the exercise of founder's share warrants.
7,777,943 388,897€ 76,864,308€
2020 Shares issued following the exercise of Stock Options. 11,000 550€ 15,950€
Capital increase in cash through the issue of 2,446,285 shares with attached equity warrants priced at €11,5 per share, of which €0.05 is nominal value and €11,45 share premium, the 29th of March 2021. Shares issued following the exercise of Stock-options, free Shares, founder's share warrants and BSA.
3,355,024 167,751€ 34,827,677€
2022 Shares issued following the exercise of free Shares and Stock Options. 308,000 15,400€ 76,725€ Capital increase in July 2023 with removal of preferential subscription rights, for a subscription price of €4.70 each, including €4.65 of issue premium, by issue of 2,380,668 ordinary shares by way of private placement and 88.491 new ordinary shares by way of public offering, for the benefit of individual investors via the PrimaryBid platform. Shares issued following the exercise of stock options, free shares and BSAs.
2,603,159 130,158€ 11,514,939€
2024 Shares issued following the exercise of free Shares and Stock Options. 112,375 5,619€ 7,250€ On July 21, 22 and 31 and August 5, 2025, capital increase by an issue of 14,424,541 ABSA (representing an issue of 14,424,541 new shares and 14,424,541 BSA at a fixed unit subscription price of €1.66 per share, including €1.61 issue premium.
Shares issued following the exercise of free Shares, Stock Options, warrants as well as bonds redeemable in shares.
18,234,375 911,719€ 30,275,598€
Capital increase in June 2026 with the cancellation of preferential subscription rights, at a subscription price of €5.00 per share (comprising a €4.95 share premium), involving the issuance of 8,000,000 ordinary shares via a public offering, 2,000,000 new ordinary shares under a reserved offering, and 480,000 ordinary shares to a specific category of persons.
Shares issued following the exercise of free Shares, Stock Options, warrants as well as bonds redeemable in shares.
12,259,280 612,964€ 54,095,516€
Share capital as of June 30, 2026 49,010,638 2,450,532€
P a g e | - 12 - Half-year Financial Report as of June 30, 2026
1. Presentation of the Group
D. SHAREHOLDING STRUCTURE AS OF JUNE 30, 2026
Summary Table
Chart
Companies % Shares
Ann-Helene & Fredrik Ljungström 10.64% 5,215,396
Katarina Martinson AB 8.81% 4,320,000
Celestial successor fund LP 5.21% 2,553,312
Venture S.à r.l. 3.09% 1,512,000
Furui Medical Science Company Luxembourg 3.08% 1,507,692
Lion Point Capital LP 3.07% 1,506,024
Founders, Management, Employees 2.80% 1,370,544
Others 63.30% 31,025,670
Total as of June 30, 2026 100.00% 49,010,638
P a g e | - 13 - Half-year financial report as of June 30, 2026
2. Condensed interim financial statements
CONDENSED INTERIM FINANCIAL STATEMENTS
The figures and information presented are based on the Group's consolidated financial statements, prepared on a voluntary basis and in accordance with IFRS accounting rules as adopted by the European Union.
MEDIAN Technologies ("the Company") is a French joint stock company (Société Anonyme) with a Board of Directors founded in 2002 and domiciled in France.
The Company's registered office is located at Les Deux Arcs - 1800 Route des Crêtes – 06560 Valbonne. The main fields of activity of the Company and its subsidiaries (together referred to as "the Group") are software publishing and the provision of services in the area of medical imaging for oncology. The Group develops and markets software solutions and offers services optimizing the use of medical images for diagnosis and followup of patients suffering from cancer.
The Company has been listed on the Euronext Growth market in Paris since 2011 (formerly Alternext- Code : ALMDT - ISIN : FR0011049824).
The Group's financial statements as of June 30, 2026 have been prepared on a going concern basis.
The consolidated financial position for the period ended June 30, 2026, came to €78,009k.
The consolidated income statement for the financial year shows a loss of €26,937k.
The reporting period covers the six months from January 1, 2026, through June 30, 2026.
P a g e | - 14 - Half-year financial report as of June 30, 2026
2. Condensed interim financial statements
A. CONSOLIDATED STATEMENT OF FINANCIAL POSITION
ASSETS (in thousands of euros) Notes 2026-06-30 2025-12-31
Intangible assets 3 1,647 1,769
Tangible assets 4 2,225 2,270
Non-current financial assets 5 490 478
Total non-current assets 4,362 4517
Inventories 25 80
Trade and other receivables 6 5,662 6,517
Current financial assets 7 184 163
Other current assets 8 6,949 6,349
Cash and cash equivalents 9 60,828 18,246
Total current assets 73,647 31355
TOTAL ASSETS 78,009 35,872
Liabilities (in thousands of euros) Notes 2026-06-30 2025-12-31
P a g e | - 17 - Half-year financial report as of June 30, 2026
2. Condensed interim financial statements
E. CONSOLIDATED STATEMENT OF CASH FLOWS
2026-06-30 2025-12-31 2025-06-30
(6 Months) (12 months) (6 months)
Consolidated net reult 25 (26,937) (34,069) (9,207)
Allowances net of amortization, depreciation and provisions 1,157 3,138 1,277
Payment based on shares 22 7,046 543 335
Gains and losses on disposals - (1) (1)
Cost of net financial debt 15 2,536 4,535 1,882
Change in the fair value of warrants 14 7,336 12,211 (2,321)
Other non-cash changes (897) (1,233) (823)
Tax charge for the period , including deferred tax 24 161 147 (32)
OPERATING CASH FLOW (9,598) (14,728) (8,890)
Changes in operating working capital requirement (475) (1,035) 1,305
Paid Interests (649) (1,479) (635)
Paid taxes 1,669 (184) 1,369
Net cash flow from operating activities (9,053) (17,426) (6,851)
Impact of changes in scope
Outflows on acquisitions of intangible assets (446) (743) (370)
Outflows on acquisitions of tangible assets (107) (4) -
Inflows on disposal of tangible and intangible assets - - -
Outflows on acquisitions of financial assets (33) (77) 76
Inflows on disposal of financial assets - - -
Net cash flow from investing activities (586) (824) (294)
Capital increase or contributions 10 53,922 29,417 1,972
Costs on capital increase 10 (831) - -
Net disposal (acquisition) of treasury shares 27 36 (74)
Loans Subscriptions 14 1,028 20,516 2,093
Loans Issuance costs - (54) -
Loans reimbursment - (20,073) -
Repayment of debt related to rights to use of lease assets 14 (2,006) (1,409) (483)
Net cash flow from financing activities 52,140 28,433 3,508
Impact of changes in exchange rates 109 (97) (148)
Net change in cash and cash equivalents 42,611 10,086 (3,784)
Cash and cash equivalents at start of the period 9 18,214 8,129 8,129
Cash and cash equivalents at end of the period 9 60,825 18,214 4,344
Consolidated Statement of Cash Flows
(In thousands of euros) Notes
P a g e | - 18 - Half-year financial report as of June 30, 2026
2. Condensed interim financial statements
F. NOTES TO THE FINANCIAL STATEMENTS (IN ACCORDANCE WITH IFRS
NOTE 1 OVERVIEW OF MAJOR EVENTS a) iCRO business
Revenue reached €11.8m in the first half of 2026, up 4.4% from €11.3m in the first half of 2025, reflecting the strong commercial momentum of the Company’s imaging services.
Revenue for the second quarter of 2026 stood at €5.9m, an increase of 11.3% compared to the €5.3m recorded in the second quarter of 2025.
As of June 30, 2026, the Group’s order backlog reached €82.4m (€80.3m at constant exchange rates since January 1, 2026), the highest level in Median Technologies’ history and a source of significant visibility regarding future revenue generation. The backlog grew from €79.8m on March 31, 2026, and €71.3m on June 30, 2025 (+15.6%), reflecting sustained demand from biopharmaceutical companies and the continued strengthening of the Company’s iCRO business.
In 2026, Median continues to roll out its three-pillar strategy to drive growth in its iCRO business:
Becoming the preferred imaging services provider for new major pharmaceutical groups.
Strengthening partnerships with global CROs.
And pursuing geographic expansion into high-growth markets for clinical trials, particularly East Asia. Median Technologies implements this strategy by leveraging not only its core imaging services but also Imaging Lab a dedicated unit within the iCRO division that provides biopharmaceutical companies with AI-driven decision-making tools.
Imaging Lab delivers high-value-added services that set the company apart from the competition and acts as a powerful catalyst for enhancing the appeal of Median’s entire imaging service portfolio to biopharmaceutical companies.
The Group is also continuing the operational initiatives aimed at improving the profitability of the iCRO business.
b) Eyonis® business
The first half of 2026 was a pivotal period for eyonis® LCS, the AI-based medical device software developed by Median to assist in the detection and diagnosis of lung cancer within screening programs. In February 2026, Median obtained US market authorization (FDA 510(k) clearance) for eyonis® LCS. This authorization marked a major strategic milestone, enabling the Company to launch the commercialization of eyonis® LCS in the United States, the world’s largest and most mature market for lung cancer screening. On July 3, 2026, Median announced that eyonis® LCS had received CE marking under the European Medical Device Regulation (MDR), paving the way for its commercialization across the European Economic Area. Complementing the FDA clearance, the CE mark significantly expands the Company’s addressable market and further strengthens the global commercial potential of eyonis® LCS.
Publication réglementée diffusée via info-financière (AMF).
Type : Informations réglementées périodiques
Sous-type : Rapports financiers et d'audit semestriels/examens réduits
ISIN : FR0011049824
Diffuseur : BWR